Northeast Pharmaceutical (000597.SZ): Net profit of 576.33,900 yuan in the first quarter decreased 17.72% year-on-year
Gelonghui, April 26 | Northeast Pharmaceutical (000597.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1.94 billion yuan, down 17.58% year on year; net profit attributable to shareholders of listed companies was 576.339 million yuan, down 17.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 298.409 million yuan, down 32.96% year on year; basic earnings per share were 0.040 yuan
Biotech Co., Ltd. (600201.SH) announced first-quarter results, net profit of 106 million yuan decreased by 1.05% year-on-year
Biotech Co., Ltd. (600201.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 348 million yuan, a year-on-year decrease of 4.42%; net profit attributable to shareholders of listed companies of 106 million yuan, a year-on-year decrease of 1.05%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 95.32%, a year-on-year decrease of 5.32%; and basic earnings per share.
Express News | Tiantan Biotech: Net profit for the first quarter was 317 million yuan, up 20.91% year-on-year
China Galaxy released a research report on April 24 stating that it gave Colon Pharmaceutical (002422.SZ) a recommended rating. The main reasons for the rating include: 1) Infusion continues to exceed expectations, demand is strong & structure is optimize
China Galaxy released a research report on April 24 stating that it gave Colon Pharmaceutical (002422.SZ) a recommended rating. The main reasons for the rating include: 1) Infusion continues to exceed expectations, demand is strong & structure is optimized, and it will continue to grow rapidly in the future; 2) the antibiotic leader is expected to continue to grow rapidly due to sharp rise in volume and price reduction and efficiency; 3) Collombotai's milestone revenue continues to be realized, and SKB264 is ready for commercialization soon. (Mainichi Keizai Shimbun)
Express News | Hualan Biotech: Net profit from mother in the first quarter was 262 million yuan, down 25.56% year on year
Placo (603566.SH): Net profit of 27.307 million yuan in the first quarter fell 57.36% year on year
On April 25, GLONGHUI (603566.SH) released its first quarter report. Operating revenue was 235 million yuan, down 23.27% year on year, net profit of 27.307 million yuan, down 57.36% year on year, after deducting non-net profit of 265.35,800 yuan, down 56.10% year on year, with basic earnings of 0.08 yuan per share.